By Darren Jones
As we hopefully near the end of the coronavirus pandemic, the life sciences industry must take note of the tremendous success achieved through profound collaboration.
Our response has brought out the best characteristics of the pharmaceutical, medical device, and medical diagnostics industries. Many innovators in the industry have been generously rewarded by investors, with impressive gains in market capitalization, while others have faced significant headwinds arising from changing commercial strategies or delayed clinical development programs. Overall, however, there has been a great inflow of capital available for development or licensing strategies.